NIH Scientists Visualize how Cancer Chromosome Abnormalities form in Living Cells
News Aug 09, 2013
The abnormality, called a translocation, occurs when part of a chromosome breaks off and becomes attached to another chromosome.
Chromosomes are thread-like structures inside cells that carry genes and function in heredity. Human chromosomes each contain a single piece of DNA, with the genes arranged in a linear fashion along its length.
Chromosome translocations have been found in almost all cancer cells, and it has long been known that translocations can play a role in cancer development. However, despite many years of research, just exactly how translocations form in a cell has remained a mystery. To better understand this process, the researchers created an experimental system in which they induced, in a controlled fashion, breaks in the DNA of different chromosomes in living cells. Using sophisticated imaging technology, they were then able to watch as the broken ends of the chromosomes were reattached correctly or incorrectly inside the cells.
Translocations are very rare events, and the scientists’ ability to visualize their occurrence in real time was made possible by recently available technology at NCI that enables investigators to observe changes in thousands of cells over long time periods. “Our ability to see this fundamental process in cancer formation was possible only because of access to revolutionary imaging technology,” said the study’s senior author, Tom Misteli, Ph.D., Laboratory of Receptor Biology and Gene Expression, Center for Cancer Research, NCI.
The scientists involved with this study were able to demonstrate that translocations can occur within hours of DNA breaks and that their formation is independent of when the breaks happen during the cell division cycle. Cells have built-in repair mechanisms that can fix most DNA breaks, but translocations occasionally occur.
To explore the role of DNA repair in translocation formation, the researchers inhibited key components of the DNA damage response machinery within cells and monitored the effects on the repair of DNA breaks and translocation formation. They found that inhibition of one component of DNA damage response machinery, a protein called DNAPK-kinase, increased the occurrence of translocations almost 10-fold. The scientists also determined that translocations formed preferentially between pre-positioned genes.
“These observations have allowed us to formulate a time and space framework for elucidating the mechanisms involved in the formation of chromosome translocations,” said Vassilis Roukos, Ph.D., NCI, and lead scientist of the study.
“We can now finally begin to really probe how these fundamental features of cancer cells form,” Misteli added.
This research was supported by the Intramural Research Program of the NCI’s Center for Cancer Research.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018